Pancreatic cancer

No risk from aspirin in pancreatic cancer

Aspirin and/or non-aspirin NSAID use is thought to reduce the risk of several cancers, but studies in pancreatic cancer with animals and patients have yielded conflicting results regarding the relationship of these drugs. Now, in a pooled analysis of two large prospective cohorts (n = 141,940) from the Health Professionals Follow-up Study and the Nurses' Health Study, no association was identified between regular aspirin and/or non-aspirin NSAID use and the incidence of pancreatic cancer. Several analytical approaches were used to account for a range of time periods between NSAID use and the development of cancer, but the lack of association was consistent. However, in a subgroup analysis, regular aspirin use was associated with reduced pancreatic cancer risk among participants with diabetes mellitus (relative risk, 0.71; 95% CI 0.54–0.94).


  1. 1

    Khalaf, N. et al. Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies. Gastroenterology (2017)

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dickson, I. No risk from aspirin in pancreatic cancer. Nat Rev Gastroenterol Hepatol 15, 68 (2018).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing